These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 36111007)
21. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma. Shen S; Yan J; Zhang Y; Dong Z; Xing J; He Y Ann Transl Med; 2021 Jan; 9(1):59. PubMed ID: 33553352 [TBL] [Abstract][Full Text] [Related]
22. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients. Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357 [TBL] [Abstract][Full Text] [Related]
23. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Hu Y; Chen Y Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315 [TBL] [Abstract][Full Text] [Related]
24. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma. Zhao J; Lin X; Zhuang J; He F Front Genet; 2021; 12():714697. PubMed ID: 34777460 [No Abstract] [Full Text] [Related]
25. m6A regulator-mediated methylation modification patterns and tumor microenvironment immune infiltration with prognostic analysis in esophageal cancer. Sheng G; Wang T; Gao Y; Wu H; Wu J Sci Rep; 2023 Nov; 13(1):19670. PubMed ID: 37952076 [TBL] [Abstract][Full Text] [Related]
26. The N6-methyladenosine methylation landscape stratifies breast cancer into two subtypes with distinct immunological characteristics. Chen Y; Hou Y; Li S; Qin W; Zhang J Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13875. PubMed ID: 38797522 [TBL] [Abstract][Full Text] [Related]
27. Action of m6A-related gene signatures on the prognosis and immune microenvironment of colonic adenocarcinoma. Shugao H; Yinhang W; Jing Z; Zhanbo Q; Miao D Heliyon; 2024 Jun; 10(11):e31441. PubMed ID: 38845921 [TBL] [Abstract][Full Text] [Related]
28. Thyroid cancer risk prediction model using m6A RNA methylation regulators: integrated bioinformatics analysis and histological validation. Zhou W; Lin J; Liu J; Zhang R; Fan A; Xie Q; Hong L; Fan D Aging (Albany NY); 2023 Feb; 15(3):846-865. PubMed ID: 36791151 [TBL] [Abstract][Full Text] [Related]
29. Comprehensive Analysis of N6-Methyladenosine-Related IncRNAs Prognostic Signature and the Associated Immune Infiltrates in Kidney Renal Clear Cell Carcinoma. Chen X; Wang L; Tu J; Pan X; Li Y; Yin H; Wang M; Yuan X Crit Rev Eukaryot Gene Expr; 2022; 32(1):79-98. PubMed ID: 35377983 [TBL] [Abstract][Full Text] [Related]
30. Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma. Zhang Y; Li L; Ye Z; Zhang L; Yao N; Gai L Ann Transl Med; 2021 Oct; 9(20):1554. PubMed ID: 34790760 [TBL] [Abstract][Full Text] [Related]
31. Analysis and prognostic significance of tumour immune infiltrates and immune microenvironment of m6A-related lncRNAs in patients with gastric cancer. Huang J; Song J; Li X; Liu S; Huang W; Shen Z; Cheng Y; Kou S; Gao Z; Tian Y; Hu J BMC Med Genomics; 2022 Jul; 15(1):164. PubMed ID: 35879790 [TBL] [Abstract][Full Text] [Related]
32. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma. Qi LW; Jia JH; Jiang CH; Hu JM Front Genet; 2020; 11():614566. PubMed ID: 33519919 [TBL] [Abstract][Full Text] [Related]
33. Characterization of m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration in acute myeloid leukemia. Han S; Qi J; Fang K; Wang H; Tang Y; Wu D; Han Y Cancer Med; 2022 Mar; 11(5):1413-1426. PubMed ID: 35023630 [TBL] [Abstract][Full Text] [Related]
34. Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs. Zhang L; Tang X; Wan J; Zhang X; Zheng T; Lin Z; Liu T Front Mol Biosci; 2021; 8():715764. PubMed ID: 34733885 [No Abstract] [Full Text] [Related]
35. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma. Meijing Z; Tianhang L; Biao Y Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200 [No Abstract] [Full Text] [Related]
36. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer. Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X Front Immunol; 2022; 13():976107. PubMed ID: 36091006 [TBL] [Abstract][Full Text] [Related]
37. An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. Du Y; Ma Y; Zhu Q; Liu T; Jiao Y; Yuan P; Wang X Front Pharmacol; 2021; 12():707930. PubMed ID: 34248650 [No Abstract] [Full Text] [Related]
38. m Liao X; Chen L; Liu J; Hu H; Hou D; You R; Wang X; Huang H Epigenetics; 2023 Dec; 18(1):2160134. PubMed ID: 36567510 [TBL] [Abstract][Full Text] [Related]
39. Construction and validation of a m6A RNA methylation and ferroptosis-related prognostic model for pancreatic cancer by integrated bioinformatics analysis. Wu T; Qian TY; Lin RJ; Jin DD; Xu XB; Huang MX; Ji J; Jiang F; Pan LL; Luo L; Ji YF; Chen QL; Xiao MB J Gastrointest Oncol; 2022 Oct; 13(5):2553-2564. PubMed ID: 36388690 [TBL] [Abstract][Full Text] [Related]
40. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation. Quan Y; Zhang X; Ping H Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]